Arvinas, in collaboration with Pfizer, has announced vepdegestrant NDA acceptance by the FDA for breast cancer treatment.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.